Shares of Enanta Pharmaceuticals Inc.
ENTA,
gained 5% premarket on Tuesday after the biotech company released positive results from an early-phase clinical trial of a treatment for respiratory syncytial virus, or RSV. EDP-323, an oral antiviral that received Food and Drug Administration fast-track designation in April, demonstrated safety and tolerability and will be advanced to a human challenge study by early in the fourth quarter, the company said in a release. The FDA’s fast-track program aims to streamline the development and review of drugs for serious conditions that have the potential to address unmet medical needs. RSV generally causes mild, cold-like symptoms but can cause severe illness, particularly in infants and older adults.
